Articles

Patients with essential thrombocythemia and myelofibrosis enroll in various studies in both academic and community centers across the United States. The comparison of patient characteristics across these centers may provide valuable insight into the management of these myeloproliferative neoplasms.

Conditioning regimens for allo-HSCT includes either myeloablative conditioning or reduced-intensity conditioning. The use of fludarabine/busulfan appears to deliver better patient outcomes after transplant compared with other commonly used conditioning regimens.

Clinical trials have demonstrated JAK2 inhibition with fedratinib effectively reduces spleen volume and improves symptoms in patients with myelofibrosis. It has yet to be determined whether spleen size before fedratinib therapy influences these effects.

Low-dose ruxolitinib is an approved therapy for patients with myelofibrosis who have thrombocytopenia, but efficacy may be limited. Evidence from PERSIST-2 indicate pacritinib at full dose may provide additional clinical benefit with a similar safety profile compared with ruxolitinib.

Pacritinib is currently under investigation in multiple trials and demonstrated efficacy and safety in patients with advanced myelofibrosis during the study period. Patients who continue pacritinib on a compassionate-use basis show further improvement in clinical outcomes.

Patients with myelofibrosis who are refractory to JAK inhibitors often lack effective treatment options that not only manage symptoms but can also reduce disease progression. Navtemadlin may improve disease burden in these patients through disease modification.

Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data.

Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset.

Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept.

Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells.